LOGIN  |  REGISTER

Latest Medical Device News

Medtronic: New Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved

April 18
Last Trade: 82.60 -0.10 -0.12

Latest approval expands Medtronic CGM portfolio in the U.S. GALWAY, Ireland, April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync™ sensor for use with the MiniMed™ 780G system. With this approval, the MiniMed™ 780G system now offers more flexibility for users of the company's most advanced insulin...Read more


Edwards Lifesciences: Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue

April 18
Last Trade: 71.53 0.33 0.46

CAIRO / Apr 18, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves. For more than 65 years, Edwards has been the leader in heart valve innovations. To create a more durable heart...Read more


Bruker Introduces nVista 2P Miniature Microscope

April 17
Last Trade: 36.28 -1.46 -3.87

Revolutionizing Neural Circuit Imaging in Freely Behaving Animal Research SAN JOSE, Calif. / Apr 17, 2025 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced the launch of the nVista 2P miniature, two-photon microscope, a groundbreaking addition to the Inscopix product line for functional imaging of freely behaving animals. It leverages advanced two-photon fluorescence microscopy technology to enable high-resolution imaging...Read more


Nano-X Imaging Receives FDA Clearance for General Use of New Imaging System, Nanox.ARC X

April 17
Last Trade: 5.20 0.70 15.56

First FDA clearance for Nanox.ARC X to produce tomographic images for general use, including musculoskeletal, pulmonary, intra-abdominal and paranasal indications Enhanced imaging system features sleek design with smaller footprint; simplified ‘plug and play’ installation process System design enables software upgrades and new capabilities to be added remotely following future regulatory clearances PETACH TIKVA, Israel,...Read more


United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Disease Test for Early Detection of Kidney Damage

April 17
Last Trade: 0.51 0.09 21.40

Regulatory milestone enables commercial expansion into high-need international market 10-minute test detects early signs of kidney damage using a simple urine sample Addresses global public health burden of Chronic Kidney Disease (CKD), with high relevance in the UAE IRVINE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that its Fortel®...Read more


electroCore: gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries

April 17
Last Trade: 6.02 0.04 0.67

ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025 International Brain Injury Association World Congress highlights the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI). Dr. Michael...Read more


CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

April 17
Last Trade: 1.03 0.01 0.98

Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., April 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the...Read more


Autonomix Medical Granted New European Patent for Proprietary Catheter-Based Technology

April 16
Last Trade: 1.85 0.08 4.52

New patent underscores breadth of application and expansion opportunities for Company’s catheter-based technology  Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, April 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...Read more


Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

April 16
Last Trade: 2.10 0.02 0.96

By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep...Read more


Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%

April 16
Last Trade: 0.45 0.05 13.67

Healthcare Focused Long-term Investors Support Strategic Vision Accelerating Shift to Higher-Margin Orthobiologics Supported by New Product Launches BELGRADE, Mont., April 16, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced the completion of a secondary private...Read more


Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

April 16
Last Trade: 130.98 1.28 0.99

First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09 First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1 Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increase Reported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0...Read more


Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring

April 16
Last Trade: 36.28 -1.46 -3.87

Bruker and RECIPE are pioneering the high-throughput ‘chrom-free’ ClinDART triple-quad MS platform for robust and cost-effective therapeutic drug monitoring assays MUNICH / Apr 16, 2025 / Business Wire / Bruker Corporation (NASDAQ: BRKR) today announced a majority investment in RECIPE Chemicals + Instruments GmbH, based in Munich, Germany. RECIPE is a leading European provider of vendor-agnostic therapeutic drug monitoring (TDM) and...Read more


Hyperfine Enrolls Initial Patients in NEURO PMR Study to Evaluate Use of AI-Powered Portable MRI in Neurology Offices

April 15
Last Trade: 0.70 0.03 4.10

Real-world study will assess clinical utility and patient experience across diverse neurological conditions to support adoption of AI-powered portable MRI systems in the office setting. GUILFORD, Conn. / Apr 15, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging...Read more


Tivic Health Systems Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia

April 15
Last Trade: 3.50 -0.18 -4.89

FREMONT, Calif. / Apr 15, 2025 / Business Wire / Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod™ for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5)...Read more


Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

April 15
Last Trade: 1.06 0.01 0.95

ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc. ("Okava"), a clinical-stage company focused on diseases of aging in dogs and cats, today announced an expansion of their collaboration to include dogs in the development of...Read more


Vivos Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™

April 15
Last Trade: 0.10 -0.02 -13.79

Kennewick, WA, April 15, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to share new developments in its ongoing human clinical trial in India for RadioGel® Precision Radionuclide Therapy™, an FDA-designated Breakthrough Device for the treatment of solid tumors. The latest results highlight both technical progress and growing clinical validation. This update builds upon the initial results released in February 2025, which...Read more


Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market

April 15
Last Trade: 1.42 0.03 2.16

Seventh generation of industry-leading personal exoskeleton is now available nationwide for individuals with spinal cord injury New and improved features streamline user experience for greater control, engagement, and confidence during walking in everyday environments MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in...Read more


Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs

April 15
Last Trade: 0.94 -0.01 -1.32

New indications discovered by applying active machine learning and using samples from the company’s vast biobank of live-cell tumors specimens Builds upon Predictive’s biomarker discovery platform to select targeted patient cohorts to significantly de-risk clinical trials PITTSBURGH, April 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has made...Read more


FDA Clears Ceribell’s Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older

April 15
Last Trade: 14.85 0.36 2.48

SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next generation Ceribell Clarity™ algorithm for the detection of electrographic seizures in patients ages 1...Read more


Profound Medical AUA 2025 Investor Event Agenda

April 15
Last Trade: 4.78 0.06 1.27

TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its hybrid (in-person and virtual) investor event taking place on Monday, April 28, 2025, during the American Urological...Read more


908 Devices Announces Preliminary First Quarter 2025 Financial Results

April 15
Last Trade: 4.95 0.42 9.27

At least 55% reported revenue growth from continuing operations compared to prior year BOSTON / Apr 15, 2025 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing...Read more


Bluejay Diagnostics Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

April 15
Last Trade: 1.99 -0.22 -9.95

ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company’s lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025. Results from SYMON-I, a pilot clinical study of interleukin-6 (IL-6) in sepsis patients intended or...Read more


Milestone Scientific Reports Year-End 2024 Financial Results and Reports Strong Outlook for 2025

April 15
Last Trade: 0.90 -0.003 -0.33

Reports expansion of CompuFlo® Epidural System across additional pain management clinics and ambulatory surgery centers following Medicare price assignment in multiple U.S. states ROSELAND, N.J., April 15, 2025 (GLOBE NEWSWIRE) --  Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and...Read more


Biomerica Reports Third Quarter Fiscal 2025 Financial Results

April 15
Last Trade: 0.51 0.09 21.40

Total Revenue Increases 10% Year-Over-Year Delivers Improved Gross Margins, Achieves Annual Cost Savings Target Early, and Reduces Cash Burn Over 55% IRVINE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2025 ended February 28, 2025. Key...Read more


NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO Fertility, Inc.”

April 14
Last Trade: 1.90 0.06 3.26

Public company to operate under new name and concentrate on building, acquiring and operating fertility clinics and the distribution of FDA-cleared INVOcell device Private company to operate as NAYA Therapeutics and focus on clinical development of bifunctional antibodies SARASOTA, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc. (the “Company”) (Nasdaq: NAYA), a healthcare...Read more


Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025

April 14
Last Trade: 1.01 -0.02 -1.94

MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results Total revenue is expected to...Read more


Kestra Medical Technologies Reports Third Quarter Fiscal 2025 Financial Results

April 14
Last Trade: 0 0.00 0.00

KIRKLAND, Wash., April 14, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) (“Kestra”), a wearable medical device and digital healthcare company, today reported financial results for the third quarter fiscal 2025, which ended January 31, 2025. Recent Highlights Q3 FY25 revenue and gross margin were in line with the preliminary estimated financial results previously disclosed in the company’s IPO...Read more


Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

April 14
Last Trade: 1.69 0.03 1.69

HOUSTON, TX, April 14, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is pleased to announce that the United States Patent and Trademark Office (USPTO) has officially granted its patent titled "Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder...Read more


Edwards Lifesciences SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System

April 14
Last Trade: 71.53 0.33 0.46

IRVINE, Calif. / Apr 14, 2025 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the company’s SAPIEN technology, the SAPIEN M3...Read more


Venus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common Stock

April 14
Last Trade: 2.89 -0.46 -13.73

TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 386,700 shares of common stock at a purchase price of $4.06 per share. H.C. Wainwright & Co. acted as the exclusive placement...Read more


Theralase Technologies Closes Non-Brokered Private Placement

April 14
Last Trade: 0.20 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has...Read more


Lucid Diagnostics Announces Closing of Public Offering of Common Stock

April 11
Last Trade: 1.21 0.12 11.01

NEW YORK, April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock, including 1,875,000 shares issued pursuant to the exercise of the underwriters'...Read more


Venus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

April 11
Last Trade: 2.89 -0.46 -13.73

TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 386,700 shares of common stock at a purchase price of $4.06 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to...Read more


Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

April 11
Last Trade: 1.94 0.09 4.86

SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), as monotherapy in patients with histologically...Read more


PROCEPT BioRobotics Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas

April 10
Last Trade: 53.03 0.22 0.42

SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Aria Resort in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Guests are encouraged to...Read more


MiMedx to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences

April 10
Last Trade: 6.68 0.05 0.75

MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will participate in the following industry conferences this quarter to feature the latest scientific and clinical data supporting the use of its portfolio of Advanced Wound Care and Surgical Solutions. “MIMEDX’s ongoing commitment to innovation and our expanding, best-in-class body of scientific and...Read more


Sanara MedTech to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

April 10
Last Trade: 29.48 0.79 2.75

FORT WORTH, TX, April 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that management will present at the Planet MicroCap Showcase: VEGAS 2025 in...Read more


Intuitive: U.S. FDA clears first stapler designed for single-port robotic surgery

April 10
Last Trade: 482.74 1.40 0.29

SUNNYVALE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food & Drug Administration (FDA) cleared the company’s fully wristed SP SureForm 45 stapler for use with its da Vinci SP surgical system in thoracic, colorectal, and urologic procedures. Like its multiport...Read more


Establishment Labs Provides Preliminary First Quarter Results and Announces an Investor Day on June 12

April 10
Last Trade: 31.45 1.27 4.21

NEW YORK / Apr 10, 2025 / Business Wire / Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, provided preliminary first quarter 2025 sales results and announced that it will host an analyst and investor event in New York City on June 12, 2025. Establishment Labs’ preliminary unaudited revenue for the...Read more


Theralase Technologies: Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments

April 10
Last Trade: 0.20 0.00 0.00

Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light,...Read more


Venus Concept Announces Closing of $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

April 10
Last Trade: 2.89 -0.46 -13.73

TORONTO, April 10, 2025 (GLOBE NEWSWIRE) --  Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 328,573 shares of common stock at a purchase price of $3.50 per share. H.C. Wainwright & Co. acted as the exclusive...Read more


Myomo Announces Upcoming Changes to its Board of Directors

April 10
Last Trade: 4.36 0.09 2.11

BURLINGTON, Mass. / Apr 10, 2025 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that directors Amy Knapp and Yitzchak Jacobovitz have informed the board they will not stand for re-election as Class II directors. Ms. Knapp has been a director since...Read more


Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

April 9
Last Trade: 11.63 0.08 0.69

QUEENSBURY, N.Y. / Apr 09, 2025 / Business Wire / Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a comparative analysis from the randomized cohort of the Company’s Phase 3 FOCUS study in Annals of Surgical Oncology. The study, titled “An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best...Read more


Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients’ Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

April 9
Last Trade: 0.24 0.0095 4.12

GARDEN CITY, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the publication of its scientific article, “A Pilot Study to Assess the Effect of Intermittent Inhaled Nitric Oxide as Treatment of Nontuberculous...Read more


ReShape Lifesciences Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

April 9
Last Trade: 0.31 -0.05 -14.62

IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has signed an agreement with Haifa, Israel-based Motion Informatics to exclusively import and distribute their next-generation neuromuscular rehabilitation devices in the U.S. The flagship product, the Stimel-03, was showcased at the American...Read more


AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

April 9
Last Trade: 9.21 0.19 2.11

VALENCIA, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced 16 abstracts to be presented at the American Burn Association (ABA) 2025 Annual Meeting, taking place April 8-11 in Phoenix, Arizona. The presentations will feature real-world and clinical data on AVITA Medical’s wound care...Read more


CYduct Diagnostics: Groundbreaking Study on Risk Assessment of Breast Cancer Aims to Revolutionize Diagnosis and Treatment

April 9
Last Trade: 0.20 0.00 0.00

WESTPORT, CT / ACCESS Newswire / April 9, 2025 / CYduct Diagnostics, Inc. (OTCPK:CYDX) ("CYduct", or the "Company"), a precision medicine-based women's health company focused on the development of breast cancer risk assessment test and diagnostic tools, today announced it is expanding its patient study research on targeted breast cancer biomarkers for risk assessment leading to early detection. A new study directed by CYduct Diagnostics,...Read more


Merit Medical Systems Launches the Ventrax™ Delivery System

April 9
Last Trade: 90.89 0.32 0.35

SOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit’s latest addition to its growing electrophysiology (EP) and cardiac rhythm management (CRM) portfolio. The portfolio provides a unique selection of solutions to improve cardiac...Read more


Microbot Medical Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System

April 9
Last Trade: 2.49 0.03 1.22

Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of...Read more


Beta Bionics to Host Investor Event on June 22, 2025

IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it will host an investor event on Sunday, June 22, 2025, in conjunction with the 85th Scientific Sessions of the American Diabetes Association (ADA) taking place June 20-23, 2025, in Chicago, IL. The event will begin at 7:00 am Central...Read more


Venus Concept Announces $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

April 9
Last Trade: 2.89 -0.46 -13.73

TORONTO, April 09, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 328,573 shares of common stock at a purchase price of $3.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to...Read more


Lucid Diagnostics Announces Proposed Public Offering of Common Stock

April 9
Last Trade: 1.21 0.12 11.01

NEW YORK, April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its intention to offer shares of common stock through an underwritten public offering. The Company also plans to grant the underwriters a 45-day option to purchase additional shares of common...Read more


SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)

April 8
Last Trade: 28.00 0.00 0.00

SANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 revenue increased between 57% and 61% compared to Q1 2024. UltraMIST revenues for Q1 2025 increased by more than 65% versus Q1 2024 and accounted for approximately 99% of the Company’s total revenues. EDEN PRAIRIE, Minn., April...Read more


Autonomix Medical Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

April 8
Last Trade: 1.85 0.08 4.52

Company on track to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX, April 08, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has engaged U.S. and...Read more


FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

April 8
Last Trade: 1.25 -0.03 -2.34

DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (FDA) has granted SeaStar Medical two new Breakthrough Device Designations for its Selective Cytopheretic Device (SCD) therapy. The two new...Read more


OrthoPediatrics Expands Scoliosis Portfolio with Launch of VerteGlide™ System

April 8
Last Trade: 21.00 0.41 1.99

WARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the U.S. launch of the new VerteGlide Spinal Growth Guidance System, used to treat Early Onset Scoliosis (“EOS”). This represents the company’s 80th system designed to treat musculoskeletal issues in children. VerteGlide...Read more


NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

April 8
Last Trade: 10.79 0.36 3.45

Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1 Long-term seizure reduction with a median reduction of 82% at 3 years. Seizure freedom with 42% of patients remaining seizure free for 6+ months.i MOUNTAIN VIEW, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the...Read more


VentriPoint Diagnostics Appoints Nicolas Coutin to Oversee Clinical Affairs

April 8
Last Trade: 0.14 0.005 3.85

Toronto, Ontario – TheNewswire - April 8, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) today announced that it has appointed Nic Coutin, PhD. to oversee Clinical Affairs. In this role he will be providing leadership to the Company’s ongoing research, translational science, and clinical studies. Nicolas will report directly to Hugh MacNaught, President and CEO. Dr. Coutin was part of the...Read more


Nyxoah Provides Update on FDA Approvable Letter for Genio System

April 8
Last Trade: 6.04 0.02 0.33

Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), which develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced an update on the FDA approval process for the Genio system. On March 26, 2025, the...Read more


CVRx Reports Preliminary First Quarter 2025 Financial Results

April 7
Last Trade: 6.25 0.10 1.63

MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. “While we continue to make significant progress in driving adoption of Barostim, first quarter revenue fell short of our expectations,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “A core element of the...Read more


NEXGEL to Present at the Planet MicroCap Showcase in Las Vegas, NV April 22nd-24th 

April 7
Last Trade: 2.83 0.00 0.00

LANGHORNE, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will be presenting at the Planet MicroCap Showcase: Vegas 2025, taking place at the Paris Hotel & Casino, Las...Read more


Inspira Technologies Announces Successful Treatment of First Patient with INSPIRA ART100 at Westchester Medical Center

April 7
Last Trade: 0.59 -0.03 -4.28

RA'ANANA, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the successful completion of the first human treatment using its U.S. Food and Drug Administration-cleared INSPIRA™ ART100 system in a critical life-support procedure. The procedure was successfully performed by...Read more


BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company

April 7
Last Trade: 21.91 -0.35 -1.57

Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash., April 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy...Read more


ICU Medical Introduces Its New Category of Infusion Devices With FDA Clearances of Plum Solo™ and Plum Duo™ Precision IV Pumps

April 7
Last Trade: 138.67 -0.47 -0.34

New devices address infusion delivery variability and expand the ICU Medical IV Performance Platform. SAN CLEMENTE, Calif., April 7, 2025 /PRNewswire/ -- ICU Medical Inc. (NASDAQ:ICUI), a worldwide leader in the development, manufacture and sale of innovative medical devices, has announced 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Plum Solo™ precision IV pump, a single-channel complement to...Read more


Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above

April 7
Last Trade: 246.80 -3.93 -1.57

New Diabetes Canada Guidelines1 recommend people with type 1 diabetes use an Automated Insulin Delivery System (AID) System for diabetes management Approximately 300,000 Canadians have type 1 diabetes, with the number of cases growing at an estimated 4.4% per year2 The Omnipod 5 System is designed to be customer-centric and aims to deliver exceptional ease of use. It has demonstrated strong clinical results including lower...Read more


Theralase Technologies: Ruvidar Demonstrates 7 Year Complete Response

April 7
Last Trade: 0.20 0.00 0.00

Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with Light-Activated Ruvidar(TM) Demonstrates 7 Year Complete Response Toronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation,...Read more


Bruker Announces First-of-a-kind 1.3 GHz High-Resolution NMR System

April 7
Last Trade: 36.28 -1.46 -3.87

Novel hybrid LTS-HTS superconducting magnet enables high-resolution for liquids and solids ultra-high field NMR research in biomolecular and advanced materials sciences ASILOMAR, Calif. / Apr 07, 2025 / Business Wire / At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the successful development and testing of the world’s first...Read more


Bruker Introduces Innovative Fourier 80 Multinuclear Benchtop FT-NMR

April 7
Last Trade: 36.28 -1.46 -3.87

Unique Fourier 80 ‘Multi-Talent’ offers 1H NMR and choice of 15 X-nuclei with just one click ASILOMAR, Calif. / Apr 07, 2025 / Business Wire / At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the ‘Multi-Talent’ configuration. This novel Fourier...Read more


MedX Health Announces Initial Closing of Non-Brokered Private Placement

April 7
Last Trade: 0.07 0.00 0.00

MISSISSAUGA, Ontario / Apr 07, 2025 / Business Wire / MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it has completed the Initial Closing of the Non-brokered Private Placement to accredited investors announced in its Press Release dated February 25, 2025. The Initial Closing comprised the issuance of 13,500,000 Units (as described below) and raised cash proceeds of $945,000. A cash commission of $7,280...Read more


Treace Medical Concepts Announces Upcoming Board Chair Transition

April 7
Last Trade: 6.45 -0.07 -1.07

PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace,...Read more


ReShape Lifesciences Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

April 7
Last Trade: 0.31 -0.05 -14.62

Significant Reduction in Overall Operating Expenses of 41.9% in 2024, Excluding M&A Related Expenses, Compared to 2023 Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Remain on Track Strategic Business Update Call to be Held Thursday, April 10, at 4:30 pm ET IRVINE, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss...Read more


AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

April 3
Last Trade: 9.21 0.19 2.11

VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. Cohealyx is designed to facilitate cellular migration and revascularization, thereby providing an...Read more


Electromed to Present at the LD Micro Invitational XV

April 3
Last Trade: 22.79 0.12 0.53

New Prague, Minnesota--(Newsfile Corp. - April 3, 2025) - Electromed, Inc. (NYSE American: ELMD) announced today that it will be participating in the 15th Annual LD Micro Invitational at the Westin Grand Central in New York on April 9th and 10th, 2025. Electromed, Inc. is scheduled to present on April 10, 2025 at 02:30 PM. Jim Cunniff, President and Chief Executive Officer, will be representing the company. Interested parties may...Read more


Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US

April 3
Last Trade: 212.91 1.42 0.67

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified, accurate, and efficient way to diagnose obstructive sleep...Read more


Autonomix Medical to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)

April 3
Last Trade: 1.85 0.08 4.52

THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO), being held April 13-16,...Read more


NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

April 3
Last Trade: 10.79 0.36 3.45

MOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held in San Diego from April 5 – 9. This includes an oral presentation on data from the Post-Approval Study (PAS) of the RNS® System in...Read more


Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting

April 3
Last Trade: 1.48 0.02 1.37

Data Also Highlights Continued Clinical Advances Using the CyberKnife System That are Making High Quality Care an Option for People Who Previously Had Limited Choices MADISON, Wis., April 3, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data on the clinical use of the CyberKnife® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors....Read more


NeuroOne Medical Technologies Announces Proposed Public Offering of Common Stock

April 3
Last Trade: 0.58 0.02 2.73

EDEN PRAIRIE, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock. All of the shares of common stock to be sold in the...Read more


RxSight Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

April 2
Last Trade: 14.43 -0.09 -0.62

ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern...Read more


Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

April 2
Last Trade: 2.32 0.22 10.48

Introduction of EluPro at Heart Rhythm 2025 in San Diego, April 25-27, 2025 SILVER SPRING, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, is proud to announce the debut of its EluPro™ Antibiotic-Eluting BioEnvelope designed for cardiac implantable electronic devices (CIEDs) and neurostimulators at the Heart Rhythm Society’s...Read more


Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits

April 2
Last Trade: 277.35 -0.44 -0.16

ALAMEDA, Calif., April 2, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The data showed that CAVT as a frontline therapy for blood clots not only improved clinical and functional outcomes but can also help reduce...Read more


Masimo to Present in the 24th Annual Needham Virtual Healthcare Conference

April 2
Last Trade: 152.15 0.47 0.31

IRVINE, Calif. / Apr 02, 2025 / Business Wire / Masimo (NASDAQ: MASI) today announced that its management will participate in the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 2:15 p.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is...Read more


Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

April 2
Last Trade: 1.69 0.03 1.69

HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego (UCSD), in collaboration with the VA San Diego Healthcare System (San Diego VA). The company began treatment...Read more


Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

April 2
Last Trade: 92.54 0.49 0.53

Clareon PanOptix Pro provides unprecedented 94% light utilization, resulting in half the light scatter of Clareon PanOptix1,2,§,* Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast1,† Commercially available in the U.S. in May, Clareon PanOptix Pro is the next generation of the world’s leading trifocal IOL3-5,‡ GENEVA / Apr 02, 2025 / Business...Read more


Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities

April 2
Last Trade: 1.09 -0.02 -1.36

Akoya’s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative The unprecedented scale of the initiative requires the high plex and high throughput of Akoya’s PhenoCycler-Fusion platform to process thousands of patients' samples MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The...Read more


Aurora Spine Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™ Sacroiliac Fusion System

April 2
Last Trade: 0.31 -0.01 -3.12

CARLSBAD, California, April 02, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the publication of a new clinical study titled "Fixation of the Sacroiliac Joint: A Cadaver-Based Concurrent-Controlled Biomechanical Comparison of Posterior Interposition and...Read more


Bruker Announces Introduction of Revolutionary d-DNP Polarizer for MRI Research and for Dynamic Nuclear Polarization Liquids NMR

April 2
Last Trade: 36.28 -1.46 -3.87

First successful customer installation of novel dissolution d-DNP Polarizer at UCSF SAN FRANCISCO / Apr 02, 2025 / Business Wire / Bruker Corporation today announced the introduction of its groundbreaking dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer at the 2025 Hyperpolarized Carbon-13 MRI Technology Development Workshop at the University of California San Francisco (UCSF) Hyperpolarized MRI Technology Resource Center....Read more


AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

April 2
Last Trade: 9.52 0.06 0.63

LATHAM, N.Y. / Apr 02, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025. Fiscal Year 2025 Third Quarter...Read more


LeMaitre Vascular to Present at the 24th Annual Needham Virtual Healthcare Conference

April 1
Last Trade: 86.28 1.61 1.90

BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:45 PM EDT. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company...Read more


Milestone Scientific Expands CompuFlo® Epidural System Footprint with InfiniSurg in New Jersey

April 1
Last Trade: 0.90 -0.003 -0.33

ROSELAND, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that InfiniSurg, LLC, a premier ambulatory surgery center based in New Jersey, has incorporated the CompuFlo® Epidural System into its clinical practice. The device will be utilized by Roman Kosiborod, DO, a highly experienced...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Medical Device Gainers

 
CompanyChangeLast Trade
Inspire Medical Systems 3.30 2.25 $150.21
TransMedics 2.86 3.35 $88.24
STERIS 2.21 1.00 $222.23
LeMaitre Vascular 1.61 1.90 $86.28
Semler Scientific 1.48 4.77 $32.49
Glaukos 1.46 1.64 $90.26
ResMed 1.42 0.67 $212.91
Intuitive 1.40 0.29 $482.74
Abbott 1.28 0.99 $130.98
CooperCompanies 1.28 1.64 $79.51
Establishment Labs 1.27 4.21 $31.45
Teleflex 1.27 0.99 $129.48
Baxter 1.07 3.85 $28.89
Hologic 1.06 1.88 $57.56
Zimmer Biomet 0.98 1.01 $97.92

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE